Table 3.
Other types of vaccine trials for glioblastoma.
| Trial nameClinicalTrial.gov identifier | Phase | Type of vaccine | Immune targets | Associated treatments in active arm | Control | Sample size(evaluable patients) | T cell response(CD4/CD8 response details) | Humoral response | Median PFS(months) | MedianOS(months) | Primary endpoint | Results |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04015700 | I | DNA | Personalized neoantigen | None | None | 6 | Ongoing (not yet recruiting) |
Ongoing (not yet recruiting) | Ongoing (not yet recruiting) | Ongoing (not yet recruiting) |
Safety | Ongoing (not yet recruiting) |
| VXM01 NCT03750071 |
I/II | DNA | VEGFR2 | Avelumab | None | 30 | Ongoing | Ongoing | Ongoing | Ongoing | Safety | Ongoing |
| Gliovac – ERC1671 NCT01903330 (145) |
II | Tumor cells | Autologous inactivated tumor cells mixed with tumor cell lysates | Cyclophosphamide plus Bevacizumab | placebo plus bevacizumab | 84 | Ongoing | Ongoing | Ongoing | Ongoing | OS and PFS | Ongoing |
| HSPPC-96 NCT00293423 (146) |
I | HSPPC-96 -peptides | autologous tumor-derived HSPPC-96 | None | None | 12 | Yes (CD8 response in 92% patients - analyzed via re-stimulation essay) |
NA | NA | 36.0 | Safety | Safe vaccine |
| HSPPC-96 NCT00905060 (147) |
II | HSPPC-96 -peptides | autologous tumor-derived HSPPC-96 | Temozolomide | None | 46 | Results pending | Results pending | 17.8 | 23.8 (44.7 in patients with low PD-L1 expression) |
Safety, survival | Results pending |
| NSPPC-96 NCT00293423 (148) |
II | HSPPC-96 -peptides | autologous tumor-derived HSPPC-96 | Temozolomide | None | 41 | NA | NA | 19.1 | 42.6 | Safety | Safe vaccine |
| ALLIANCE NCT01814813 (149) |
II | HSPPC-96 -peptides | autologous tumor-derived HSPPC-96 | Bevacizumab | Bevacizumab | 90 | Results pending | Results pending | Results pending | Results pending (interim results : 7.5) | OS | Negative |
| NCT03018288 | II | HSPPC-96 -peptides | autologous tumor-derived HSPPC-96 | Temozolomide and pembrolizumab | TMZ and Pembrolizumab plus placebo | 108 | Ongoing | Ongoing | Ongoing | Ongoing | OS12 | Ongoing |
| NCT03650257 | II | HSPPC-96 -peptides | HSPPC-96 | Temozolomide | Temozolomide | 150 | Ongoing | Ongoing | Ongoing | Ongoing | OS12 | Ongoing |
HSPPC-96, heat-shock protein peptide complex 96; KLH, keyhole limpet haemocyanin; PD-L1, Programmed death-ligand 1; PFS, progression free survival; OS, overall surviva.